Takuya Maemoto

Pharmacological Characterization of FR194921, a New Potent, Selective, and Orally Active Antagonist for Central Adenosine A1 Receptors

Takuya Maemoto, Miho Tada, Takuma Mihara et al. · Journal of Pharmacological Sciences · 2004 · 78 citations · Full text

Pharmacological Characterization of a Simple Behavioral Response Mediated Selectively by Central Adenosine A1 Receptors, Using In Vivo and In Vitro Techniques

Hugh Marston, Keith Finlayson, Takuya Maemoto et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 62 citations

Species differences in brain adenosine A₁ receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists

Takuya Maemoto, Keith Finlayson, Henry J. Olverman et al. · British Journal of Pharmacology · 1997 · 58 citations · Full text

A Novel Potent Radical Scavenger, 8-(4-Fluorophenyl)-2-((2 E)-3-phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c] [1,2,4]triazine (FR210575), Prevents Neuronal Cell Death in Cultured Primary Neurons and Attenuates Brain Injury after Focal Ischemia in Rats

Akinori Iwashita, Takuya Maemoto, Hirohisa Nakada et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 32 citations

Neuroprotective efficacy of FR901459, a novel derivative of cyclosporin A, in in vitro mitochondrial damage and in vivo transient cerebral ischemia models

Yuko Muramatsu, Yasuhisa Furuichi, Nobuteru Tojo et al. · Brain Research · 2007 · 30 citations

Mitochondrial Function, Vitro Mitochondrial Damage, Medicine +13